Table 1.

Modeled projected effectiveness of RV5 against RGE-related hospitalizations by country

	Projected effectiveness: Base case scenario† (%)	Projected effectiveness: Sensitivity analysis§ (%)
China	89	83
Hong Kong	94	93
India	82	70
South Korea	91	89
Taiwan	93	90
Thailand	86	75

^†Base case scenario: assumes 50% efficacy against mixed and nontypeable serotypes.

^§Sensitivity analysis: assumes 0% efficacy against mixed and nontypeable serotypes. RGE, rotavirus gastroenteritis; RV5, oral pentavalent rotavirus vaccine.